Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
To identify tumor specific DNA mutations and aberrations and to follow these in blood over time to predict treatment response/survival and secondly to correlate presence of these markers in blood to pathological parameters (LVI, Pn, WPOI and margins), radiological findings and to tumor stage.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Patient with head and neck cancer | Patient diagnosed with head and neck cancer |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| DNA exome sequencing of tumor and blood | Genetic | A piece from tumor and a blood sample will be collected during surgery. DNA will be extracted and presence of tumor specific mutations/aberrations will be analysed with a DNA exome seq panel. Presence of identified markers will be followed in blood samples with the same panel and these blood samples will be collected in routine follow-up during the first two years. Presence of markers over time in blood will be correlated to outcomes 1-5. |
| Measure | Description | Time Frame |
|---|---|---|
| Recurrence | Recurrent disease within 2 years after surgery. Is presence of these DNA changes in blood correlated to recurrence? | 2 years |
| Survival | Alive/dead. Is presence of these DNA changes in blood correlated to survival? | 2 years |
| Treatment response | Is presence of these DNA changes in blood correlated to treatment response? | 6 months |
| Measure | Description | Time Frame |
|---|---|---|
| Pathological parameters | Is presence of these DNA changes correlated to pathological parameters (LVI, Pn, WPOI and margins). | 6 months |
| Radiological parameters | Is presence of these DNA markers in blood correlated to PET-findings? |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
All patients diagnosed with a primary head and neck cancer Nov 2023 to May 2024 at Karolinska will be asked to participate.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Anders Näsman, MD PhD | Contact | +46812370000 | anders.nasman@ki.se |
| Name | Affiliation | Role |
|---|---|---|
| Anders Näsman, MD PhD | Karolinska institutet and Karolinska Universitetssjukhuset | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Karolinska universitetssjukhuset | Recruiting | Stockholm | 17176 | Sweden |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D006258 | Head and Neck Neoplasms |
| ID | Term |
|---|---|
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
Not provided
Not provided
| ID | Term |
|---|---|
| D001800 | Blood Specimen Collection |
| ID | Term |
|---|---|
| D013048 | Specimen Handling |
| D019411 | Clinical Laboratory Techniques |
| D019937 | Diagnostic Techniques and Procedures |
| D003933 | Diagnosis |
Not provided
Not provided
Not provided
Not provided
Not provided
DNA extracted from tumour and blood
|
| 9 months |
| Stage | If patients are stratified by stage, are there any differences in Outcome 1-5 (please see above) | 2 years |
| D011677 | Punctures |
| D013514 | Surgical Procedures, Operative |
| D008919 | Investigative Techniques |